DefinitionThis section has been translated automatically.
Virustatic. Nucleoside inhibitor of HIV reverse transcriptase.
Half-lifeThis section has been translated automatically.
39 hours.
You might also be interested in
IndicationThis section has been translated automatically.
Antiretroviral combination therapy for the treatment of HIV-1 infection in treatment-naive or previously treated patients > 3 months. Also approved as a combination preparation with tenofovir disoproxil(TDF) for HIV-PrEP.
Pregnancy/nursing periodThis section has been translated automatically.
Strict indication during pregnancy (insufficient data available). Contraindicated during breastfeeding or during therapy weaning (it is not known whether the substance passes into breast milk).
Dosage and method of useThis section has been translated automatically.
Adults/youth/children > 4 months and > 33 kg KG: once/day 200 mg p.o.
Undesirable effectsThis section has been translated automatically.
Frequent headaches, gastrointestinal symptoms such as nausea, vomiting. Occasionally neutropenia, anemia, hypertriglyceridemia, hyperglycemia.
PreparationsThis section has been translated automatically.
Emtriva
Prof. Dr. med. Peter Altmeyer